Novo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
21/09/2023 17:26
COPENHAGEN, Sept 21 (Reuters) - Novo Holdings, the
controlling shareholder in drugmaker Novo Nordisk NOVOb.CO , on
Thursday said it had closed its acquisition of biopharmaceutical
company Paratek Pharmaceuticals in a deal valued at $462
million.
The acquisition of Paratek Pharmaceuticals, which was
announced in early June, is Novo Holdings' largest individual
investment in antimicrobial resistance therapies to date, it
said in a statement.
Novo Holdings, which controls 76% of the votes in Denmark's
Novo Nordisk NOVOb.CO last week announced a major investment
in a new energy transition fund, as it is looking to expand its
portfolio beyond health.
(Reporting by Louise Breusch Rasmussen, editing by Jane
Merriman)
((Louisebreusch.rasmussen@tr.com; +45 21 27 97 79;))
Recent news on Paratek Pharmaceuticals
See all newsNovo Holdings closes $462 mln acquisition of Paratek Pharmaceuticals
Brief: Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Responds to Demand Letters From 11 Stockholders Alleging 'Misleading', Incomplete Statements In Proxy Statement Filed On June 30
Brief: Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote For Acquisition By Gurnet Point Capital And Novo Holdings
Brief: Paratek Pharmaceuticals Announces Second Quarter 2023 Revenue Of $40.0 Million